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Introduction: Surveillance systems enable optimal care delivery and appropriate resource allocation, yet
Canada lacks a dedicated surveillance system for chronic kidney disease (CKD). Using data from the
Canadian Primary Care Sentinel Surveillance Network (CPCSSN), a national chronic disease surveillance
system, this study describes the geographic, sociodemographic, and clinical variations in CKD prevalence
in the Canadian primary care context.
Methods: This cross-sectional study included 559,745 adults in primary care in 5 provinces across Canada
from2010 through2015.Datawereanalyzedbygeographic (urbanor rural residence), sociodemographic (age,
sex, deprivation index), and clinical (medications prescribed, comorbid conditions) factors, using data from
CPCSSN and the Canadian Deprivation Index. CKD stage 3 or higher was deﬁned as 2 estimated glomerular
ﬁltration rate (eGFR) values of <60 ml/min per 1.73 m2 more than 90 days apart as of January 1, 2015.
Results: Prevalence of CKD was 71.9 per 1000 individuals and varied by geography, with the highest
prevalence in rural settings compared with urban settings (86.2 vs. 68.4 per 1000). CKD was highly
prevalent among individuals with 3 or more other chronic diseases (281.7 per 1000). Period prevalence of
CKD indicated a slight decline over the study duration, from 53.4 per 1000 in 2010 to 46.5 per 1000 in 2014.
Conclusion: This is the ﬁrst study to estimate the prevalence of CKD in primary care in Canada at a national
level. Results may facilitate further research, prioritization of care, and quality improvement activities to
identify gaps and improvement in CKD care.
Kidney Int Rep (2019) 4, 561–570; https://doi.org/10.1016/j.ekir.2019.01.005
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C KD is a major public health burden both nationallyand internationally. The global mean prevalence of
CKD is 13.4%, and within Canada, most recent
estimates suggest at least 4 million people have the
disease.1,2 CKD poses a signiﬁcant burden on the health
care system: recent estimates of health care costs for
Canadians with CKD exceed $40 billion annually.1 This
condition is more common among people with cardio-
vascular disease, hypertension, and diabetes, all of
which have adverse health outcomes.3 Individuals with
CKD are at increased risk of premature mortality, hos-
pitalization, and acute kidney injury.2 Most patients
with CKD can be effectively managed in primary care.4
See Commentary on Page 513
Correspondence: Aminu K. Bello, Division of Nephrology and
Immunology, Department of Medicine, University of Alberta,
11–107 Clinical Sciences Building, 8440 112 Street NW, Edmonton,
Alberta, Canada T6B 2B7. E-mail: aminu1@ualberta.ca
Received 18 July 2018; revised 16 December 2018; accepted 7
January 2019; published online 21 January 2019
Kidney International Reports (2019) 4, 561–570 561
CLINICAL RESEARCH
Although no Canada-wide data are available, upward of
95% of patients with CKD in Alberta are managed in
primary care, making primary care data very relevant.5
Reliable surveillance data is important at multiple
levels (i.e., local, provincial/state, national) to ascertain
variations in processes of care, as well as treatment and
disease burden, which can drive improvements in care
delivery. These measures inform optimal care delivery
and have implications for increased life span, improved
quality of life, and lower individual and societal
costs.4–7 A national surveillance system is particularly
suited for CKD, as the diagnosis is based on easily
obtainable laboratory measures. Presently in Canada,
there is no uniﬁed system to capture national CKD
surveillance data.6,7 In the absence of this, an existing
pan-Canadian surveillance system, the CPCSSN,8 can be
used for epidemiological studies of chronic diseases.
The CPCSSN is a network of primary care practices that
provide care to more than 1.5 million individuals across
Canada and pool their data from electronic medical
records (EMRs) to a central repository enabling disease
surveillance from a primary care perspective. This data
source is appropriate for our study given that most
patients with CKD are managed in primary care.4,5 The
CPCSSN was designed to collect and maintain national
epidemiological surveillance data to improve outcomes
in primary care and optimize chronic disease manage-
ment.8 The data have undergone processing to achieve
a standardized format to allow for jurisdictional com-
parisons of many chronic conditions.
This cross-sectional study leverages data derived
from individuals’ EMRs available in the CPCSSN to
deﬁne the burden of moderate-to-advanced CKD (stages
3–5) and identify gaps in care. Speciﬁcally, the objec-
tives of this study were to leverage the CPCSSN to (i)
estimate the prevalence and range of severity of CKD in
the Canadian primary care context; and (ii) describe
geographic, sociodemographic, and clinical variations
in CKD prevalence. This information will help ascertain
the burden of CKD in Canada and identify modiﬁable
care gaps in the optimal management of this important
health condition.
METHODS
The details of this project are described elsewhere.9 We
brieﬂy outline the methodological approach for this
analysis in the following sections.
Data Sources
The CPCSSN is a national disease surveillance system
composed of 12 regional practice-based primary care
research networks that collect primary care health in-
formation in 8 of 13 provinces and territories in Canada
(Figure 1).10–12 Past literature comparing CPCSSN data
with Canadian census data has determined that age- and
sex-adjusted prevalence rates are reasonably representa-
tive of the general primary care population.10 Primary
care providers (PCPs) contributing data to the CPCSSN
were found to be younger and work more frequently in
academic settings than colleagues in family medicine,10
although the practices were found to be representative
of primary care practices using EMRs.13 PCPs voluntarily
contribute de-identiﬁed data; approximately every 6
months data are cleaned, coded, processed, and made
available for surveillance, research, quality improvement
initiatives, and clinical decision-making. During the
study period, validated algorithms were used to monitor
the following chronic diseases and neurological condi-
tions: hypertension, osteoarthritis, diabetes, chronic
obstructive pulmonary disease, depression, Alzheimer’s
and related dementias, epilepsy, and Parkinson’s disease.
The deﬁnitions used a combination of International
Classiﬁcation of Diseases, Ninth Revision codes and
numeric and textual data drawn from diagnosis, billing,
laboratory test results, and prescribed medication data, as
available in patient charts.11 Although there are addi-
tional relevant comorbidities in relation to CKD, these
have not yet been validated for use in the CPCSSN and
therefore were not examined in this study.
Participants and Setting
For this study, data were extracted from the CPCSSN for
the period January 1, 2010, through December 31, 2015.
A baseline cohort of individuals whose PCP was a
CPCSSN sentinel was identiﬁed based on the following
criteria: participants were seen by a provider included in
the CPCSSN, had a valid date of birth in the system, were
at least 18 years of age, and had 2 or more measures of
eGFR in a 1-year period following their index date (date
of ﬁrst eGFR entry in their CPCSSN record) (Figure 2). All
these measures are ambulatory-based, and no hospital-
based (acute care) data were included during the study
period. Serum creatinine measurements were used to
calculate eGFR using the CKD Epidemiology Collabora-
tion equation. Serum creatinine measurements were
calibrated to the standard isotope dilution mass spec-
trometry. Before 2012, the Modiﬁcation of Diet and Renal
Disease study equation was the standard equation to
calculate eGFR in Canada; however, for consistency, any
measurements before 2012 were manually calculated us-
ing the CKD Epidemiology Collaboration equation. The
CKD Epidemiology Collaboration equation has been
found to more accurately estimate eGFR than the Modi-
ﬁcation of Diet and Renal Disease study equation14 and
has been endorsed by Kidney Disease Improving Global
Outcomes and the Canadian Society of Nephrology.
Individuals in the baseline cohort were identiﬁed as
having CKD if they had 2 eGFR values of <60 ml/min
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per 1.73 m2 more than 90 days apart as of January 1,
2015. We considered only those with advanced stages
of CKD (stages 3–5), as eGFR alone is insufﬁcient to
indicate the presence of CKD in less advanced stages.
Those diagnosed with ESRD and on dialysis or having
renal transplantation were excluded. This deﬁnition
was based on existing national and international CKD
frameworks and conventions.15,16
This study drew data from 5 provinces (British
Columbia, Alberta, Manitoba, Ontario, and Nova
Scotia), which together account for approximately 70%
of the Canadian population. Although Canada main-
tains a universal health care system, the delivery,
management, and organization of health services are
overseen by the province or territory of residence.
Covariates
Data from the study cohort were analyzed according
to geographic, sociodemographic, and clinical factors.
Geography included province and urban or rural
residence, deﬁned using standard methods based on
postal code data.17,18 Sociodemographic factors
included age, sex, and material deprivation. Material
deprivation was calculated using postal code data
extracted from the EMR and linked to the Canadian
Deprivation Index, an ecological measure of material
deprivation expressed as a quintile (1–5; with 1 being
least deprived and 5 most deprived). The Canadian
Deprivation Index score for each postal code is derived
from census data from 2011 on rates of home ownership,
educational level, and food security. Canadian Depriva-
tion Index data are made available by the federal gov-
ernment for research purposes.19 Clinical factors included
medications prescribed and comorbid conditions. All
variables were extracted from individual EMRs as avail-
able in the CPCSSN database.
Analytic Approach
Descriptive statistics were used to characterize the study
cohort. This included means and SDs for normally
distributed continuous variables, and numbers (n) and
percentages (%) for categorical variables. The unadjusted
Figure 1. Participation of Canadian Primary Care Sentinel Surveillance Network (CPCSSN) networks by province. Blue, nonparticipating
CPCSSN networks; orange, participating CPCSSN networks. Primary care research networks contributing data to the CPCSSN: 1, British
Columbia Primary Care Research Network (BCPCReN); 2, Northern Alberta Primary Care Research Network (NAPCReN); 3, Southern Alberta
Primary Care Research Network (SAPCReN); 4, Manitoba Primary Care Research Network (MaPCReN); 5, Deliver Primary Healthcare Infor-
mation Project (DELPHI); 6, McMaster University Sentinel and Information Collaboration (MUSIC); 7, University of Toronto Practice-Based
Research Network (UTOPIAN); 8, The Eastern Ontario Network (EON); 9, Ottawa Practice Enhancement Network (OPEN); 10, Réseau de
recherche en soins primaires de l’Université de Montréal (RRSPUM); 11, Maritime Family Practice Research Network (MaRNet-FP); 12, Atlantic
Practice-Based Research Network (APBRN).
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prevalence of CKD was calculated per 1000 individuals
and stratiﬁed by sociodemographic and clinical data.
Prevalence estimates for CKD were then stratiﬁed by CKD
stage, age range, sex, deprivation index, urban/rural
residence, and type and number of comorbid conditions.
Period prevalence of CKD by year, stratiﬁed by the same
variables, was also determined.
Ethics and Privacy
The data extraction process was reviewed and
approved by institutional research ethics boards in
each participating jurisdiction across Canada as well as
the Health Canada Research Ethics Board. This study
was granted approval by the CPCSSN Surveillance and
Research Standing Committee and the University of
Alberta Health Research Ethics Committee.
RESULTS
Baseline Demographics
A baseline cohort of 559,745 individuals managed in
primary care was identiﬁed, residing in Ontario
(59.4%), Alberta (16.4%), Manitoba (12.3%), Nova
Scotia (9.7%), and British Columbia (2.2%). Most in-
dividuals lived in urban areas (79.9%), and 18.5%
lived in rural areas. Mean (SD) age of the study cohort
was 48.5 (17.8) years and 60.4% were female. In-
dividuals were spread nearly evenly across the depri-
vation index (range from 8.3% to 13.2% across the 5
quintiles); however, 257,285 individuals (46.0%) had
incomplete postal code and/or census data, and were
unable to be scored. The missing postal codes might
relate to incomplete data collection on this variable
across CPCSSN networks.
Table 1. Baseline patient characteristics of the overall study
population
Patient characteristics Overall (N [ 559,745)
Age, yr, mean (SD) 48.5 (17.8)
Sex, male, n (%) 221,449 (39.6)
Age range, yr, n (%)
18–44 242,235 (43.3)
45–59 164,833 (29.4)
60–64 42,940 (7.7)
65–69 34,058 (6.1)
70–74 25,126 (4.5)
75–80 23,307 (4.2)
>80 27,246 (4.9)
Deprivation index, n (%)
1 (least deprived) 65,206 (11.6)
2 73,808 (13.2)
3 65,861 (11.8)
4 51,203 (9.1)
5 (most deprived) 46,382 (8.3)
Missing 257,285 (46.0)
Province of residence, n (%)
Ontario 332,748 (59.4)
Alberta 91,781 (16.4)
Manitoba 68,987 (12.3)
Nova Scotia 54,191 (9.7)
British Columbia 12,068 (2.2)
Urban/Rural, n (%)
Urban 447,014 (79.9)
Rural 103,627 (18.5)
Missing 9105 (1.6)
Comorbidity, n (%)
COPD 30,192 (5.4)
Dementia 18,701 (3.3)
Depression 111,938 (20.0)
Diabetes 109,395 (19.6)
Epilepsy 7556 (1.3)
Hypertension 188,076 (33.6)
Osteoarthritis 95,597 (17.1)
Parkinson disease 2767 (0.5)
Both diabetes and hypertensiona 38,966 (7.0)
Comorbidities,b n (%)
0 262,425 (46.9)
1–2 251,913 (45.0)
$3 45,407 (8.1)
Prescribed medications, n (%)
Non-ACEi/ARB antihypertensivec 452,532 (27.3)
ACEi or ARB 130,272 (23.3)
Statins 120,763 (21.6)
Metformin 42,136 (7.5)
Other diabetes medicationd 25,215 (4.5)
Insulin 15,218 (2.7)
Stage of CKD by eGFR, n (%)
Do not meet criteria (eGFR >59)e 518,244 (92.6)
3A (eGFR 45–59) 18,851 (3.4)
3B (eGFR 30–44) 14,255 (2.5)
4 (eGFR 15–29) 6559 (1.2)
5 (eGFR <15) 1836 (0.3)
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; COPD,
chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate.
aDiabetes and hypertension considered individually and as distinct comorbid group.
bBased on the above conditions alone.
cNon-ACEi/ARB antihypertensive: antihypertensive medication excluding ACEi and ARB.
dOther diabetes medication: excludes insulin and metformin.
eDo not meet criteria for CKD stages 3–5 based on eGFR only.
Figure 2. Selection of study population. CPCSSN, Canadian Primary
Care Sentinel Surveillance Network; eGFR, estimated glomerular
ﬁltration rate; PCP, primary care provider.
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During the study period, more than half of the study
population had 1 or more of the 8 listed chronic con-
ditions (53.1%), 45.0% had 1 or 2 comorbidities, and
8.1% had 3 or more comorbidities (multimorbidity). Of
these, the most common were hypertension (33.6%),
depression (20.0%), and diabetes (19.6%). The medi-
cations most commonly prescribed to individuals in the
study cohort were antihypertensive medications
(50.6%), made up of angiotensin-converting enzyme
inhibitors or angiotensin II receptor blockers (23.3%)
and non– angiotensin-converting enzyme inhibitors/
angiotensin II receptor blocker antihypertensive med-
ications (27.3%), and statins (21.6%) (Table 1).
Prevalence of CKD Overall, and Stratiﬁed by
Geography (Residence), Deprivation, Age, Sex,
and Comorbidities
At baseline, 41,501 individuals (7.4%) were identiﬁed
as having CKD stages 3 to 5. Baseline prevalence of CKD
was inversely related to severity (stage 3A [31.8 per
1000], stage 3B [25.3], stage 4 [11.7], stage 5 [3.3]).
Among individuals with complete deprivation data and
able to be assessed using the Canadian Deprivation
Index, the highest prevalence of CKD was found in the
second most deprived category (score of 4), 67.7 per
1000 individuals, and the lowest prevalence in the least
deprived category (score of 1), 52.2 per 1000 in-
dividuals (Figure 3a). There were no major differences
in sex-speciﬁc prevalence. A high prevalence of more
severe stages of CKD in elderly individuals ($65 years
of age) was observed, particularly in individuals be-
tween the ages of 75 and 80 years (345.1 per 1000) and
individuals older than 80 years (397.6 per 1000)
(Table 2). With regard to geography, CKD was more
prevalent in rural settings (86.2 per 1000) than urban
settings (68.4 per 1000) (Figure 3b). There was a high
prevalence of CKD among individuals with 3 or more
comorbidities, with an overall prevalence of 281.7 per
1000 individuals, most of whom were in stages 3A and
3B (98.9 and 109.6 per 1000). The prevalence of CKD
Figure 3. (a) Overall prevalence of chronic kidney disease (CKD) (2010–2015) by deprivation index, by CKD stage. Level of deprivation of Ca-
nadian Deprivation Index score: 1 (least deprived), dark blue; 2, red; 3, green; 4, purple; 5 (most deprived), light blue. (b) Overall prevalence of
CKD (2010–2015) by urban/rural residence, stratiﬁed by CKD stage. Participant residence: urban (blue); rural (red).
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was high among individuals with comorbid dementia
(303.3 per 1000), a combination of both diabetes and
hypertension (267.4 per 1000), Parkinson’s disease
(223.7 per 1000), and chronic obstructive pulmonary
disease (221.3 per 1000) (Table 2).
The overall prevalence of CKD declined slightly over
the course of this study, from 53.4 per 1000 in 2010 to
46.5 per 1000 in 2014 (Table 3). From 2010 to 2011,
prevalence decreased in most subgroups, and from
2011 to 2014, prevalence remained largely stable
(Figure 4a and b).
DISCUSSION
This study examined the burden of CKD in adults in
primary care in Canada and how prevalence varied by
sociodemographic and clinical characteristics. Within a
primary care setting, the estimated national prevalence
of CKD stages 3 to 5 during the study period was 71.9
per 1000 individuals, with signiﬁcant variations by
geography (urban/rural), sociodemographic factors
(age, deprivation), and clinical factors (number and
type of comorbidities).
To our knowledge, there have been no comparable
national prevalence studies of CKD in Canada. One
study, reporting 2007 to 2009 data from a national
survey, found a 12.5% prevalence of CKD in Canadian
adults,20 but reported on all stages (1–5), including
proteinuria estimates. Our study, which captures
prevalence of moderate-to-advanced CKD (stages 3–5)
and leverages eGFR criteria recorded in participating
primary care clinics, suggests a lower prevalence than
the estimated global average.2 It is possible that pre-
vious estimates, based on administrative data, would
exaggerate the true prevalence in PCPs’ EMRs. A lower
prevalence of CKD in the study cohort also could be a
result of nondiagnosis (due to lack of testing or reduced
health-seeking behavior by individuals because CKD is
considered a “silent disease”), selection bias (greater
health-consciousness among individuals engaging with
primary care), or misclassiﬁcation (potential errors
relating to incorrect laboratory dates or captured stages
3–5). Our results provide preliminary insight into
prevalence of CKD in the Canadian context and offer
opportunities to test these hypotheses in future
research.
Results indicated that individuals with any 3 co-
morbid conditions or those with the presence of dia-
betes and hypertension had a CKD prevalence that
exceeded 250 per 1000 individuals. In contrast, in-
dividuals without diabetes or hypertension, or those
with minimal comorbid conditions, had a very low
prevalence of CKD, highlighting the appropriate target
populations for screening and surveillance. The ﬁnding
that prevalence of CKD was high among individuals
with comorbid dementia and Parkinson’s disease may
be a result of the established correlation with age and
chronic disease.21
The higher overall prevalence of CKD in elderly
individuals has implications for management of the
disease, as this population also has a high rate of
comorbidities.22 This suggests long-term health service
planning frameworks should be based on multi-
morbidity, such as the framework by Bowling and
colleagues,23 rather than on a single disease. Of note,
although aging is associated with an increased risk of
developing CKD, this is speciﬁc to a subset of the
population: those with existing chronic conditions,
such as hypertension and diabetes.24 It is also possible
that, as a result of increased interaction with the health
Table 2. Prevalence of CKD stages 3–5 (2010–2015), stratiﬁed by
sociodemographic and clinical characteristics; per 1000 individuals
Characteristic Stage 3A Stage 3B Stage 4 Stage 5 Overall
Overall 31.76 25.26 11.66 3.26 71.94
Sex
Male 32.53 25.22 11.75 3.84 71.02
Female 31.27 25.28 11.60 2.88 73.34
Age range
18–45 2.32 1.28 0.71 0.52 4.82
46–59 16.16 7.88 3.54 1.63 29.21
60–64 50.79 26.06 10.43 4.31 91.59
65–69 81.57 49.00 19.58 6.34 156.50
70–74 115.46 84.26 34.43 10.47 244.61
75–80 141.33 132.36 57.41 13.94 345.05
>80 124.83 166.63 90.07 16.11 397.64
Comorbidity
COPD 76.74 82.11 48.49 13.94 221.28
Osteoarthritis 70.24 60.94 26.65 6.13 163.97
Dementia 110.21 121.81 59.78 11.50 303.30
Epilepsy 32.16 30.44 13.63 3.57 79.80
Parkinson’s disease 93.24 86.01 36.86 7.59 223.71
Depression 34.24 28.84 14.15 3.77 81.00
Diabetes 72.24 75.52 42.43 13.63 203.83
Hypertension 76.78 69.75 32.90 8.81 188.23
Both diabetes and HTN 91.95 100.11 57.36 18.02 267.44
Comorbiditiesa
0 8.31 3.37 1.23 0.50 13.41
1–2 44.10 32.86 14.24 3.91 95.10
$3 98.86 109.59 57.61 15.59 281.65
Urban/Rural
Urban 30.89 24.02 10.64 2.81 68.37
Rural 35.80 30.14 15.35 4.93 86.22
Deprivation index
1 (least deprived) 26.27 17.11 7.27 1.58 52.23
2 27.67 20.47 8.70 2.43 59.26
3 30.49 21.23 9.69 2.38 63.79
4 30.25 23.79 10.78 2.83 67.65
5 (most deprived) 25.74 23.28 10.97 2.07 62.07
Missing 36.05 30.37 14.42 4.44 85.29
Note: CKD: eGFR <60 ml/min per 1.73 m2 with at least 2 measures 90 days apart (3A
[eGFR 45–59], 3B [eGFR 30–44], 4 [eGFR 15–29], 5 [eGFR <15]).
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR,
estimated glomerular ﬁltration rate; HTN, hypertension.
aBased on the above conditions alone.
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care system, this age group is more readily identiﬁed
and diagnosed with CKD than other age groups.
Prevalence of CKD was higher in rural settings than
in urban settings. There is evidence of rural-urban
disparities in many chronic diseases, including CKD
in certain populations.25 For example, one study cites
that rural and remote indigenous populations had a 3-
fold increase in CKD prevalence compared with urban
indigenous populations.25 The results from our study
suggest that rural-urban disparities in CKD prevalence
are more widespread. Access to health services is a
barrier to optimal care in many rural and remote re-
gions of Canada due in large part to the country’s
expansive land mass and low population density.26,27
Most common determinants of remote-urban health
disparities reported in the literature include travel
distance to health care services, geographical isolation,
limited providers, and socioeconomic factors.28,29 Prior
Canadian studies have found that rural residents with
CKD have less access to specialty care and lower quality
of care than their urban counterparts.28,29 Higher
prevalence of advanced stages of CKD in rural pop-
ulations could reﬂect this issue. Although there were
signiﬁcant missing data, our ﬁndings appear to
conﬁrm, as other studies have found, a positive rela-
tionship between socioeconomic deprivation, and
prevalence of CKD.30,31 Although Canada has universal
coverage (medicare) for medically necessary physician,
hospital, and diagnostic services, many gaps exists,
including coverage for the cost of prescription drugs
and mental health care.32 This, alongside the afore-
mentioned barriers in accessing health care services,
poor health literacy, racial factors, and geography
(rural vs. urban), may particularly affect low-income
individuals,32 potentially explaining differentials in
the prevalence rate of CKD across socioeconomic strata.
Table 3. Period prevalence of CKD stratiﬁed by sociodemographic and clinical characteristics and year; per 1000 individuals
Characteristic
2010
n [ 267,658
2011
n [ 364,421
2012
n [ 419,782
2013
n [ 465,372
2014
n [ 495,550
Overall 53.36 47.38 46.66 46.82 46.53
Sex
Male 58.38 53.04 52.58 52.70 51.55
Female 50.29 43.86 42.89 43.04 43.26
Age range
18–44 5.03 4.40 4.60 4.43 4.36
45–59 23.28 19.2 19.69 21.18 22.37
60–64 67.78 55.62 55.91 60.42 62.41
65–74 145.51 119.47 117.43 123.51 129.91
75–80 249.40 208.51 207.86 214.81 221.64
>80 298.72 264.20 263.05 264.19 257.97
Comorbidity
COPD 162.79 143.84 142.47 142.83 141.75
Osteoarthritis 106.8 97.30 97.30 98.38 99.43
Dementia 217.94 193.67 187.01 184.85 177.63
Epilepsy 55.72 49.04 48.30 49.64 49.40
Parkinson’s disease 161.64 134.00 137.18 136.77 136.25
Depression 58.52 51.30 50.39 50.80 50.74
Diabetes 170.95 158.55 159.22 164.31 160.98
Hypertension 129.34 117.19 117.40 120.07 120.83
Comorbiditiesa
0 8.02 6.00 5.84 6.09 6.81
1–2 64.4 57.75 56.89 58.39 59.51
$3 206.00 185.96 186.11 189.20 188.69
Urban/Rural
Urban 49.40 43.75 44.28 45.09 45.05
Rural 68.46 60.13 55.24 52.95 51.67
Deprivation Index
1 (least deprived) 33.09 31.28 31.94 33.91 34.57
2 39.64 35.73 36.87 39.43 39.91
3 46.10 40.01 39.96 41.92 42.39
4 51.04 45.02 44.92 46.40 46.76
5 (most deprived) 49.46 43.08 45.23 47.24 46.26
Missing 67.73 59.92 56.24 53.57 52.41
Deﬁnition for CKD: eGFR <60 ml/min per 1.73m2 with at least 2 measures 90 days apart (3A [eGFR 45–59], 3B [eGFR 30–44], 4 [eGFR 15–29], 5 [eGFR <15]).
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate.
aBased on the above conditions alone.
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This knowledge of barriers to care can guide health
care planning and health-promoting initiatives and
further justiﬁes managing CKD through primary care.
Our ﬁnding that the overall prevalence of CKD,
regardless of subgroup stratiﬁed, remained generally
stable over time, is consistent with other studies.33
There was, however, a slight decrease in prevalence
among most subgroups from 2010 to 2011, followed by
relatively stable prevalence from 2011 to 2014. There
were no known changes in CKD deﬁnition, physician
reporting, or laboratory measurements to explain the
slight decrease in prevalence from 2010 to 2011; how-
ever, there was a large inﬂux of individuals (n ¼
96,763) into the CPCSSN system in 2011 increasing the
denominator, which could help to explain this ﬁnding.
Strengths and Limitations
We used a previously untapped source to estimate the
prevalence and patterns of CKD in primary care across
Canada. This study included a large population, whose
health data were collected from primary care records,
and could serve as proof of concept that the barriers to
conducting a national CKD study in Canada, such as
health service silos or the lack of a dedicated CKD
surveillance system, can be overcome. Overall, the
surveillance data captured in this study can inform
quality improvement and disease surveillance activities
across participating PCPs and provinces. Ongoing
surveillance of CKD using the methodology detailed in
this study can help target care to reduce inequity and
maximize effective resource use as well as guide policy
and research agendas. For example, this information
could be used to guide in-depth studies on disparities
in CKD burden across geographic and sociodemo-
graphic factors. It could also help inform the debate
about the balance between labeling asymptomatic risk
factors and preventing progression to symptomatic
disease.22,34 Moving forward, to address the worldwide
Figure 4. (a) Period prevalence of chronic kidney disease (CKD) by year and deprivation index. Level of deprivation of Canadian Deprivation
Index score: 1 (least deprived), dark blue; 2, red; 3, green; 4, purple; 5 (most deprived), light blue. (b) Period prevalence of CKD by year and
urban/rural residence. Participant residence: urban (blue); rural (red).
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growing public health issue of CKD, it will be
increasingly important to learn from one another and
collaborate at the international level.
This study has some noteworthy limitations that relate
to the use of EMR (point of care) data to deﬁne the
prevalence of CKD. Information in the EMR is based on
clinical encounters and might be biased by CKD detection
in high-risk populations. Furthermore, the quality and
comprehensiveness of data might have varied by region
or PCP. Another limitation in this study was incomplete
postal code data; however, we considered postal codes
only with regard to deprivation data. In addition, the
subgroup with missing postal code data was not signiﬁ-
cantly different from the subgroup with postal code data.
Furthermore, the ecological measure of deprivation is less
precise than a personal measure would be. Another lim-
itation pertained to the examination of comorbidities;
although we examined CKD in relation to certain
comorbidities, we were not able to examine all relevant
medical conditions, such as congestive heart failure,
coronary artery disease, and peripheral vascular disease,
as these have not been validated for use in the CPCSSN.
Proteinuria is an important marker of kidney damage and
quality measure for CKD and inclusion of this would
make our analysis more comprehensive; however,
because it is not collected and/or reported consistently
across primary care practices and therefore could intro-
duce bias, it was not considered in our deﬁnition of CKD.
Finally, the data did not represent every Canadian
province and territory; however, as noted previously, the
participating jurisdictions contain approximately 70% of
the total Canadian population and so are fairly
representative.
CONCLUSION
To our knowledge, this is the ﬁrst national study to es-
timate the prevalence and patterns of CKD in primary
care in Canada and to report on patterns in the distri-
bution of the disease across geographic, sociodemo-
graphic, and clinical factors. We have demonstrated the
utility of using existing surveillance networks to study
the epidemiology of CKD, even when a national system is
lacking. These ﬁndings have implications for the design
of in-depth Canadian studies to understand how the
burden of all severity levels of CKD varies by socio-
demographic and clinical factors. The ﬁndings will pro-
vide the basis for a subsequent study to better
understand these patterns and identify variation in CKD
care delivery and devise strategies to optimize care.
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